ACT-389949

ACT-389949 is a first-in-class, potent and selective and agonist of formyl peptide receptor type 2 (FPR2) /Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders[1][2].

Product Specifications

CAS Number

[1258417-54-7]

UNSPSC

12352005

Hazard Statement

H302

Target

Formyl Peptide Receptor (FPR)

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/act-389949.html

Purity

99.96

Solubility

DMSO : 10 mg/mL (ultrasonic; adjust pH to 1 with HCl)

Smiles

O=C(C1=C(C2=CC=CC(C)=C2)OC(C)=N1)NC3=NN(CC4=NC(C(F)(F)C)=CO4)N=C3

Molecular Formula

C20H18F2N6O3

Molecular Weight

428.39

Precautions

H302

References & Citations

[1]Stalder AK, et al. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. Br J Clin Pharmacol. 2017 Mar;83 (3) :476-486.|[2]Lind S, et al. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949. Biochem Pharmacol. 2019 Aug;166:163-173.